{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:26Z","timestamp":1793387126998,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2163,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Enhancing non\u2013CFTR (cystic fibrosis transmembrane conductance regulator)-mediated anion secretion is an attractive therapeutic approach for the treatment of cystic fibrosis (CF) and other mucoobstructive diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the effects of TMEM16A potentiation on epithelial fluid secretion and mucociliary clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effects of a novel low-molecular-weight TMEM16A potentiator (ETX001) were evaluated in human cell and animal models of airway epithelial function and mucus transport.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Potentiating the activity of TMEM16A with ETX001 increased the Ca2+-activated Cl\u2212 channel activity and anion secretion in human bronchial epithelial (HBE) cells from patients with CF without impacting calcium signaling. ETX001 rapidly increased fluid secretion and airway surface liquid height in CF-HBE cells under both static conditions and conditions designed to mimic the shear stress associated with tidal breathing. In ovine models of mucus clearance (tracheal mucus velocity and mucociliary clearance), inhaled ETX001 was able to accelerate clearance both when CFTR function was reduced by administration of a pharmacological blocker and when CFTR was fully functional.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Enhancing the activity of TMEM16A increases epithelial fluid secretion and enhances mucus clearance independent of CFTR function. TMEM16A potentiation is a novel approach for the treatment of patients with CF and non-CF mucoobstructive diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201908-1641oc","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T10:29:56Z","timestamp":1578047396000},"page":"946-954","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":95,"title":["TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis"],"prefix":"10.1093","volume":"201","author":[{"given":"Henry L.","family":"Danahay","sequence":"first","affiliation":[{"name":"Enterprise Therapeutics, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lilley","sequence":"additional","affiliation":[{"name":"Sussex Drug Discovery Centre, University of Sussex, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fox","sequence":"additional","affiliation":[{"name":"Sussex Drug Discovery Centre, University of Sussex, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Charlton","sequence":"additional","affiliation":[{"name":"Sussex Drug Discovery Centre, University of Sussex, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sabater","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center of Florida, Miami, Florida; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Button","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Enterprise Therapeutics, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Collingwood","sequence":"additional","affiliation":[{"name":"Enterprise Therapeutics, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gosling","sequence":"additional","affiliation":[{"name":"Enterprise Therapeutics, Brighton, United Kingdom"},{"name":"Sussex Drug Discovery Centre, University of Sussex, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"2026030321440932200_bib1","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2026030321440932200_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030321440932200_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-obstructive lung diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030321440932200_bib4","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J Clin Invest"},{"key":"2026030321440932200_bib5","doi-asserted-by":"crossref","first-page":"1801297","DOI":"10.1183\/13993003.01297-2018","article-title":"Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH","volume":"52","author":"Hill","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321440932200_bib6","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1073\/pnas.1811787115","article-title":"Roles of mucus adhesion and cohesion in cough clearance","volume":"115","author":"Button","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321440932200_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026030321440932200_bib8","first-page":"S216","article-title":"Emerging concepts and therapies for mucoobstructive lung disease","volume-title":"Ann Am Thorac Soc","author":"Mall","year":"2018"},{"key":"2026030321440932200_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1124\/jpet.102.035485","article-title":"Pharmacology of INS37217 [P(1)-(uridine 5\u2032)-P(4)- (2\u2032-deoxycytidine 5\u2032)tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis","volume":"302","author":"Yerxa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2026030321440932200_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pupt.2007.12.003","article-title":"Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3","volume":"21","author":"Kellerman","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"2026030321440932200_bib11","doi-asserted-by":"crossref","first-page":"C827","DOI":"10.1152\/ajpcell.1999.276.4.C827","article-title":"UTP inhibits Na+ absorption in wild-type and DeltaF508 CFTR-expressing human bronchial epithelia","volume":"276","author":"Devor","year":"1999","journal-title":"Am J Physiol"},{"key":"2026030321440932200_bib12","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2003755","article-title":"Mechanosensitive ATP release maintains proper mucus hydration of airways","volume":"6","author":"Button","year":"2013","journal-title":"Sci Signal"},{"key":"2026030321440932200_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.11.034","article-title":"Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis","volume":"162","author":"Moss","year":"2013","journal-title":"J Pediatr"},{"key":"2026030321440932200_bib14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1126\/science.1163518","article-title":"TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity","volume":"322","author":"Caputo","year":"2008","journal-title":"Science"},{"key":"2026030321440932200_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.09.003","article-title":"Expression cloning of TMEM16A as a calcium-activated chloride channel subunit","volume":"134","author":"Schroeder","year":"2008","journal-title":"Cell"},{"key":"2026030321440932200_bib16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nature07313","article-title":"TMEM16A confers receptor-activated calcium-dependent chloride conductance","volume":"455","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"2026030321440932200_bib17","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1113\/jphysiol.2012.240838","article-title":"Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia","volume":"590","author":"Scudieri","year":"2012","journal-title":"J Physiol"},{"key":"2026030321440932200_bib18","article-title":"The pharmacology of novel TMEM16A potentiator compounds","author":"Danahay"},{"key":"2026030321440932200_bib19","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1569-1993(19)30135-3","article-title":"WS03-6 TMEM16A potentiators: a new therapeutic opportunity for treating cystic fibrosis-related lung disease","volume":"18","author":"Danahay","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026030321440932200_bib20","first-page":"532P","article-title":"The in vitro and in vivo pharmacology of novel TMEM16A potentiator compounds","volume":"54","author":"Danahay","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2026030321440932200_bib21","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.13075","article-title":"NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia","volume":"172","author":"Coote","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2026030321440932200_bib22","doi-asserted-by":"crossref","first-page":"L226","DOI":"10.1152\/ajplung.00311.2001","article-title":"Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells","volume":"282","author":"Danahay","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026030321440932200_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1074\/jbc.M114.618140","article-title":"Variomics screen identifies the re-entrant loop of the calcium-activated chloride channel ANO1 that facilitates channel activation","volume":"290","author":"Bill","year":"2015","journal-title":"J Biol Chem"},{"key":"2026030321440932200_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1085\/jgp.117.1.53","article-title":"Polarized signaling via purinoceptors in normal and cystic fibrosis airway epithelia","volume":"117","author":"Paradiso","year":"2001","journal-title":"J Gen Physiol"},{"key":"2026030321440932200_bib25","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1074\/jbc.M410617200","article-title":"Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia","volume":"280","author":"Ribeiro","year":"2005","journal-title":"J Biol Chem"},{"key":"2026030321440932200_bib26","doi-asserted-by":"crossref","first-page":"35751","DOI":"10.1074\/jbc.M505832200","article-title":"Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections","volume":"280","author":"Tarran","year":"2005","journal-title":"J Biol Chem"},{"key":"2026030321440932200_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/rccm.201612-2445OC","article-title":"SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that restores mucus transport","volume":"196","author":"Scott","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321440932200_bib28","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1096\/fj.201600797RR","article-title":"Differential effects of anoctamins on intracellular calcium signals","volume":"31","author":"Cabrita","year":"2017","journal-title":"FASEB J"},{"key":"2026030321440932200_bib29","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1074\/jbc.M603019200","article-title":"Physiological regulation of ATP release at the apical surface of human airway epithelia","volume":"281","author":"Okada","year":"2006","journal-title":"J Biol Chem"},{"key":"2026030321440932200_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.coph.2009.02.004","article-title":"Purinergic receptors in airway epithelia","volume":"9","author":"Lazarowski","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"2026030321440932200_bib31","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1074\/jbc.M110.175109","article-title":"TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells","volume":"286","author":"Namkung","year":"2011","journal-title":"J Biol Chem"},{"key":"2026030321440932200_bib32","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1111\/bph.13201","article-title":"New selective inhibitors of calcium-activated chloride channels - T16A(inh) -A01, CaCC(inh) -A01 and MONNA - what do they inhibit?","volume":"172","author":"Boedtkjer","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2026030321440932200_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/ajrccm.150.1.8025763","article-title":"Human airway ion transport: part one","volume":"150","author":"Boucher","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321440932200_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.physiol.68.072304.112754","article-title":"Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress","volume":"68","author":"Tarran","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"2026030321440932200_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1113\/jphysiol.2006.126086","article-title":"Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia","volume":"580","author":"Button","year":"2007","journal-title":"J Physiol"},{"key":"2026030321440932200_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1191\/1479972305cd078ra","article-title":"Physiotherapy management of cystic fibrosis","volume":"2","author":"Dodd","year":"2005","journal-title":"Chron Respir Dis"},{"key":"2026030321440932200_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.rmed.2015.05.018","article-title":"Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis","volume":"109","author":"Wheatley","year":"2015","journal-title":"Respir Med"},{"key":"2026030321440932200_bib38","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1096\/fj.11-191627","article-title":"Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction","volume":"25","author":"Namkung","year":"2011","journal-title":"FASEB J"},{"key":"2026030321440932200_bib39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bph.13420","article-title":"Eact, a small molecule activator of TMEM16A, activates TRPV1 and elicits pain- and itch-related behaviours","volume":"173","author":"Liu","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2026030321440932200_bib40","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1113\/JP278784","article-title":"TRPV4 and purinergic receptor signalling pathways are separately linked in airway epithelia to CFTR and TMEM16A chloride channels","volume":"597","author":"Genovese","year":"2019","journal-title":"J Physiol"},{"key":"2026030321440932200_bib41","doi-asserted-by":"crossref","first-page":"128414","DOI":"10.1172\/jci.insight.128414","article-title":"Niclosamide repurposed for the treatment of inflammatory airway disease","volume":"4","author":"Cabrita","year":"2019","journal-title":"JCI Insight"},{"key":"2026030321440932200_bib42","doi-asserted-by":"crossref","first-page":"16354","DOI":"10.1073\/pnas.1214596109","article-title":"Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321440932200_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fphar.2019.00051","article-title":"Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways","volume":"10","author":"Miner","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/8\/946\/67180487\/ajrccm_201_8_946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/8\/946\/67180487\/ajrccm_201_8_946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:44:25Z","timestamp":1772592265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/201\/8\/946\/8496441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,15]]},"published-print":{"date-parts":[[2020,4,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201908-1641oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"2019-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}